Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. In 2018 the FDA approved endobronchial valves (EBV) as a Breakthrough Device for endobronchial lung volume reduction in the treatment of severe emphysema. The goal of this project is to develop more robust and quantitative criteria, a CT imaging biomarker, to identify patients that are likely to benefit from EBV implantation. CVIB scientists were awarded an R01 grant from the NIH to support the translational software development, led by Mike McNitt-Gray, with co-Principal Investigators Grace Kim, Jonathan Goldin, and Matt Brown. The computer vision system will analyze chest CT scans to quantitatively assess heterogeneity of emphysema and fissure completeness, markers of effective treatment. The funding awarded to support this imaging biomarker translation to clinical practice totals around $1.5M over a 4-year period to support scientists, staff, and students involved in the research.